MCID: PLY020
MIFTS: 46

Polyradiculoneuropathy

Categories: Neuronal diseases

Aliases & Classifications for Polyradiculoneuropathy

MalaCards integrated aliases for Polyradiculoneuropathy:

Name: Polyradiculoneuropathy 12 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4308
MeSH 44 D011129
SNOMED-CT 68 128078004
UMLS 73 C0032587

Summaries for Polyradiculoneuropathy

MalaCards based summary : Polyradiculoneuropathy is related to guillain-barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. An important gene associated with Polyradiculoneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are TGF-Beta Pathway and Allograft rejection. The drugs Rho(D) Immune Globulin and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and skin, and related phenotypes are homeostasis/metabolism and behavior/neurological

Related Diseases for Polyradiculoneuropathy

Diseases related to Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 guillain-barre syndrome 31.6 ALB MBP MPZ PMP2 PMP22
2 chronic inflammatory demyelinating polyradiculoneuropathy 31.5 ALB IFNG IL17A MPZ PMP22 PRF1
3 hereditary neuropathy with liability to pressure palsy 30.7 MPZ PMP22
4 neuropathy, hereditary, with liability to pressure palsies 30.4 MPZ PMP22
5 myasthenia gravis 30.1 IFNG IL10 MBP
6 neurosyphilis 30.1 IL10 IL17A
7 meningitis 30.1 ALB IFNG IL10
8 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.0 IFNG IL10 IL17A
9 chronic graft versus host disease 30.0 ALB IFNG IL10
10 helicobacter pylori infection 29.6 CCL5 IFNG IL10
11 interstitial lung disease 29.5 CCL5 IFNG IL10
12 radiculopathy 29.5 CCL5 IL10 IL17A
13 autoimmune disease 29.4 IFNG IL10 IL17A MBP
14 optic neuritis 29.2 MAG MBP MPZ
15 rabies 29.2 ALB CCL5 STAT1
16 polyneuropathy 29.1 MAG MBP MPZ PMP22
17 systemic lupus erythematosus 29.0 ALB CCL5 IFNG IL10 IL17A
18 dermatitis, atopic 29.0 CCL5 IFNG IL10 IL17A
19 hereditary neuropathies 28.8 MAG MBP MPZ PMP22
20 psoriasis 28.8 CCL5 IFNG IL10 IL17A
21 malaria 28.4 ALB CCL5 IFNG IL10 IL17A
22 demyelinating polyneuropathy 28.3 ALB MAG NFASC PMP22
23 rheumatoid arthritis 28.0 CCL5 CXCL12 IFNG IL10 IL17A
24 inflammatory bowel disease 27.4 ALB CCL5 IFNG IL10 IL17A STAT1
25 neuritis 27.1 CCL5 IFNG MAG MBP MPZ PMP2
26 multiple sclerosis 25.6 CCL5 IFNG IL10 IL17A MAG MBP
27 polyradiculoneuropathy associated with igg/iga/igm monoclonal gammopathy without known antibodies 11.9
28 chronic inflammatory demyelinating polyneuropathy 11.6
29 subacute inflammatory demyelinating polyneuropathy 11.3
30 lewis-sumner syndrome 11.3
31 guillain-barre syndrome, familial 11.2
32 chronic inflammatory demyelinating polyneuritis 11.0
33 chronic polyradiculoneuritis 10.9
34 x-linked charcot-marie-tooth disease 10.9
35 charcot-marie-tooth neuropathy type 1 10.9 MPZ PMP22
36 foot drop 10.9 MPZ PMP22
37 roussy-levy hereditary areflexic dystasia 10.9 MPZ PMP22
38 charcot-marie-tooth disease, demyelinating, type 1f 10.9 MPZ PMP22
39 charcot-marie-tooth disease, demyelinating, type 1c 10.9 MPZ PMP22
40 gastrointestinal tuberculosis 10.8 ALB IFNG
41 charcot-marie-tooth disease, demyelinating, type 1b 10.7 MPZ PMP22
42 charcot-marie-tooth disease, axonal, type 2b 10.7 MPZ PMP22
43 hyperlucent lung 10.7 IFNG IL10
44 trichosporonosis 10.7 IFNG IL17A
45 congenital hypomyelination neuropathy 10.6 MBP MPZ PMP22
46 sporotrichosis 10.6 IFNG IL10
47 motor peripheral neuropathy 10.6 MPZ PMP22
48 baylisascariasis 10.6 IFNG IL10
49 african tick-bite fever 10.6 CCL5 IFNG
50 pericardial tuberculosis 10.6 IFNG IL10

Graphical network of the top 20 diseases related to Polyradiculoneuropathy:



Diseases related to Polyradiculoneuropathy

Symptoms & Phenotypes for Polyradiculoneuropathy

MGI Mouse Phenotypes related to Polyradiculoneuropathy:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 IFNG MBP ALB IL10 IL17A MAG
2 behavior/neurological MP:0005386 10.19 MAG IFNG MBP IL10 PMP22 PRF1
3 hematopoietic system MP:0005397 10.16 MAG IFNG MBP IL10 CCL5 CXCL12
4 cellular MP:0005384 10.13 IFNG MBP ALB IL10 CXCL12 PMP22
5 immune system MP:0005387 10.1 MAG IFNG MBP IL10 CCL5 CXCL12
6 mortality/aging MP:0010768 10.06 IFNG MBP ALB IL10 CXCL12 IL17A
7 nervous system MP:0003631 9.9 IFNG MBP IL10 CXCL12 MAG PRF1
8 liver/biliary system MP:0005370 9.85 IFNG ALB IL10 CXCL12 PRF1 STAT1
9 muscle MP:0005369 9.73 CXCL12 IFNG ALB IL10 PMP22 STAT1
10 normal MP:0002873 9.5 IFNG MBP ALB IL10 CXCL12 PRF1
11 reproductive system MP:0005389 9.17 IFNG IL10 CXCL12 PMP22 MBP PRF1

Drugs & Therapeutics for Polyradiculoneuropathy

Drugs for Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
2 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
3 Antibodies Phase 4,Phase 3,Phase 2,Not Applicable
4 Immunoglobulins Phase 4,Phase 3,Phase 2,Not Applicable
5 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
6
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
7
Mycophenolic acid Approved Phase 3 24280-93-1 446541
8
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
9
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
10 glucocorticoids Phase 3,Phase 2
11 3,4-diaminopyridine Phase 3
12 Fingolimod Hydrochloride Phase 3
13 Hormone Antagonists Phase 3,Phase 2
14 Hormones Phase 3,Phase 2
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
16 Pharmaceutical Solutions Phase 3,Phase 2
17 Immunoglobulin G Phase 3,Not Applicable
18 Immunosuppressive Agents Phase 3,Phase 2
19 Potassium Channel Blockers Phase 3,Phase 2
20 Anti-Infective Agents Phase 3,Phase 2
21 Anti-Inflammatory Agents Phase 3,Phase 2
22 Antineoplastic Agents, Hormonal Phase 3,Phase 2
23 Anti-Bacterial Agents Phase 3
24 Antibiotics, Antitubercular Phase 3
25 Antitubercular Agents Phase 3
26
4-Aminopyridine Approved Phase 2 504-24-5 1727
27
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
29 Complement System Proteins Phase 2
30 interferons Phase 2
31 Adjuvants, Immunologic Phase 2
32 Micronutrients Phase 2
33 Thioctic Acid Phase 2
34 Trace Elements Phase 2
35 Vitamin B Complex Phase 2
36 Vitamins Phase 2
37 Interferon-beta Phase 2
38 Antioxidants Phase 2
39 Protective Agents Phase 2
40 Antirheumatic Agents Phase 2
41 Antiviral Agents Phase 2
42 Folate Nutraceutical Phase 2
43 Alpha-lipoic Acid Nutraceutical Phase 2
44 Vitamin B9 Nutraceutical Phase 2
45
Infliximab Approved 170277-31-3
46
Citric Acid Approved, Nutraceutical, Vet_approved Not Applicable 77-92-9 311
47 Chelating Agents Not Applicable
48 Gastrointestinal Agents
49 Dermatologic Agents
50 Vaccines

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
3 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
4 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
5 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
6 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
7 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
8 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
9 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
10 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
11 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
12 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
13 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
14 Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome Completed NCT02342184 Phase 3 GB-0998
15 Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome Completed NCT02221271 Phase 3 NPB-01
16 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
17 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
18 Interest of Mycophenolate for CIDP Weaning Active, not recruiting NCT02494505 Phase 3 Mycophenolate Mofetil;placebo
19 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
20 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
21 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
22 Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study Unknown status NCT02029378 Phase 2 Eculizumab
23 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
24 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
25 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
26 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
27 Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients Completed NCT02780570 Phase 2
28 Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine Completed NCT00056810 Phase 2 4-aminopyridine (4-AP)
29 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
30 Early Mechanical Ventilation for Guillain Barré Syndrome Completed NCT00167622 Phase 2
31 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Recruiting NCT02967679 Phase 1, Phase 2 MD1003
32 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
33 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
34 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
35 A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 Active, not recruiting NCT03275740 Phase 1 PF-06755347;Placebo comparator
36 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
37 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
38 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858 Not Applicable
39 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
40 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
41 The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation Unknown status NCT00173199
42 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
43 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
44 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
45 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678 Not Applicable
46 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
47 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
48 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614
49 Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré Syndrome Completed NCT02883270 Not Applicable
50 Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS) Completed NCT01306578 Not Applicable IVIG

Search NIH Clinical Center for Polyradiculoneuropathy

Cochrane evidence based reviews: polyradiculoneuropathy

Genetic Tests for Polyradiculoneuropathy

Anatomical Context for Polyradiculoneuropathy

MalaCards organs/tissues related to Polyradiculoneuropathy:

41
Spinal Cord, Brain, Skin, T Cells, Thyroid, Tongue, Kidney

Publications for Polyradiculoneuropathy

Articles related to Polyradiculoneuropathy:

(show top 50) (show all 535)
# Title Authors Year
1
Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin. ( 29554579 )
2018
2
IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>Ar</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. ( 29764262 )
2018
3
Parallel fluctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249367 )
2018
4
Pyrexia-associated Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. ( 29709940 )
2018
5
A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. ( 29603842 )
2018
6
DEVELOPMENT OF GANGLIONOPATHY AND TABETIC VISCERAL CRISES ON THE BACKGROUND OF POLYRADICULONEUROPATHY ASSOCIATED WITH MONOCLONAL GAMMOPATHY (CASE REPORT). ( 29578430 )
2018
7
Clinical Significance of A Waves in Acute Inflammatory Demyelinating Polyradiculoneuropathy. ( 29847438 )
2018
8
Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-BarrAc syndrome. ( 29801870 )
2018
9
Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29360221 )
2018
10
Myelitis and Polyradiculoneuropathy With Severe Pain: Unusual Neurological Manifestations as Presenting Symptoms of Brucellosis. ( 29953037 )
2018
11
Risk factors for osteoporosis in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29896772 )
2018
12
Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-Up. ( 29435815 )
2018
13
Immunohistochemistry and electrophysiological findings in swine abattoir workers with immune-mediated polyradiculoneuropathy. ( 29406910 )
2018
14
History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 29866282 )
2018
15
Diagnosing chronic inflammatory demyelinating polyradiculoneuropathy with triple stimulation technique. ( 29926221 )
2018
16
A significant correlation between cauda equina conduction time and cerebrospinal fluid protein in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249382 )
2018
17
Subacute demyelinating polyradiculoneuropathy complicating Epstein-Barr virus infection in GATA2 haploinsufficiency. ( 28093780 )
2017
18
Chronic inflammatory demyelinating polyradiculoneuropathy and anesthesia: a case series. ( 28936613 )
2017
19
Chronic inflammatory demyelinating polyradiculoneuropathy-causing myelopathy. ( 28786217 )
2017
20
Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. ( 29145880 )
2017
21
Blink R1 latency utility in diagnosis and treatment assessment of polyradiculoneuropathy-organomegaly-endocrinopathy-monoclonal protein-skin changes and chronic inflammatory demyelinating polyradiculoneuropathy. ( 28646568 )
2017
22
Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases. ( 28337614 )
2017
23
Lewis-Sumner syndrome in a patient with rheumatoid arthritis: Link between rheumatoid arthritis and demyelinating polyradiculoneuropathies. ( 28363822 )
2017
24
Multiple Sites Ultrasonography of Peripheral Nerves in Differentiating Charcot-Marie-Tooth Type 1A from Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 28522988 )
2017
25
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. ( 28084646 )
2017
26
Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29089585 )
2017
27
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. ( 28481421 )
2017
28
Early electrophysiological findings in acute inflammatory demyelinating polyradiculoneuropathy variant of Guillain-Barre syndrome in the Pakistani populationA -A a comparison with global data. ( 29091318 )
2017
29
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. ( 29185258 )
2017
30
Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). ( 29119642 )
2017
31
Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment. ( 28382108 )
2017
32
ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components. ( 29065233 )
2017
33
Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors. ( 28432982 )
2017
34
Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy. ( 28215575 )
2017
35
Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29092099 )
2017
36
Prospective comparison of acute motor axonal neuropathy and acute inflammatory demyelinating polyradiculoneuropathy in 140 children with Guillain-BarrAc syndrome in India. ( 29053890 )
2017
37
Acute Inflammatory Demyelinating Polyradiculoneuropathy Secondary to Ifosfamide. ( 28816726 )
2017
38
Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29086018 )
2017
39
Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. ( 27781132 )
2016
40
Multiple Myeloma Associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Importance of Continued Surveillance. ( 28070468 )
2016
41
Stance Postural Strategies in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 26977594 )
2016
42
Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop. ( 27241239 )
2016
43
Intravenous Immunoglobulins Lower Inflammatory Gene Expression in Skin Biopsies of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. ( 27286956 )
2016
44
Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis. ( 28607734 )
2016
45
Evolution of hepatitis E virus-associated meningo-polyradiculoneuropathy on ribavirin. ( 27470489 )
2016
46
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Clinical Features, Diagnosis, and Current Treatment Strategies. ( 27902997 )
2016
47
Giant nerves in chronic inflammatory polyradiculoneuropathy. ( 27463360 )
2016
48
A Bodybuilder With Weak Hands and Feet: Corticosteroid-Responsive Pure Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy Following Anabolic Steroid Use. ( 27438336 )
2016
49
Fatigue, Pain, Anxiety and Depression in Guillain-BarrAc Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 27077919 )
2016
50
Peripheral Nerve Ultrasonography in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: Correlations with Clinical and Neurophysiological Data. ( 27313890 )
2016

Variations for Polyradiculoneuropathy

Expression for Polyradiculoneuropathy

Search GEO for disease gene expression data for Polyradiculoneuropathy.

Pathways for Polyradiculoneuropathy

Pathways related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 CCL5 CXCL12 IFNG IL10 IL17A STAT1
2
Show member pathways
12.47 CXCL12 IFNG IL10 IL17A PRF1 STAT1
3
Show member pathways
12.37 IFNG IL10 IL17A STAT1
4
Show member pathways
12.34 IFNG IL10 IL17A STAT1
5
Show member pathways
12.16 IFNG IL10 IL17A STAT1
6
Show member pathways
11.94 IFNG IL10 IL17A STAT1
7 11.88 MAG MPZ NFASC
8 11.79 IFNG MAG MBP
9 11.76 IL10 IL17A STAT1
10 11.68 MBP MPZ PMP22
11 11.61 CCL5 CXCL12 IFNG IL10 IL17A STAT1
12 11.57 CXCL12 IFNG IL10 STAT1
13 11.54 IFNG IL10 IL17A
14
Show member pathways
11.45 CCL5 CXCL12 IFNG IL10 IL17A STAT1
15 11.41 CCL5 CXCL12 IFNG IL17A
16 10.98 IFNG IL10
17 10.31 MAG MBP

GO Terms for Polyradiculoneuropathy

Cellular components related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 paranode region of axon GO:0033270 9.16 MAG NFASC
2 compact myelin GO:0043218 9.13 MAG MBP PMP22
3 myelin sheath GO:0043209 9.1 ALB MAG MBP MPZ NFASC PMP2

Biological processes related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.73 CCL5 IL10 IL17A STAT1
2 response to virus GO:0009615 9.65 CCL5 CXCL12 IFNG
3 regulation of signaling receptor activity GO:0010469 9.65 CCL5 CXCL12 IFNG IL10 IL17A
4 peripheral nervous system development GO:0007422 9.55 NFASC PMP22
5 positive regulation of interleukin-6 secretion GO:2000778 9.54 IL17A MBP
6 positive regulation of osteoclast differentiation GO:0045672 9.52 IFNG IL17A
7 positive regulation of monocyte chemotaxis GO:0090026 9.51 CCL5 CXCL12
8 positive regulation of T cell migration GO:2000406 9.49 CCL5 CXCL12
9 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.46 IFNG STAT1
10 immune response GO:0006955 9.43 CCL5 CXCL12 IFNG IL10 IL17A MBP
11 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.4 MAG MPZ
12 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.37 IL10 MBP
13 positive regulation of interleukin-23 production GO:0032747 9.32 IFNG IL17A
14 positive regulation of killing of cells of other organism GO:0051712 9.16 IFNG PRF1
15 myelination GO:0042552 8.92 MBP MPZ NFASC PMP22

Molecular functions related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid binding GO:0005504 9.26 ALB PMP2
2 chemokine receptor binding GO:0042379 9.16 CCL5 CXCL12
3 cytokine activity GO:0005125 9.02 CCL5 CXCL12 IFNG IL10 IL17A
4 CCR5 chemokine receptor binding GO:0031730 8.96 CCL5 STAT1

Sources for Polyradiculoneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....